Home › Compare › PARPF vs JNJ

PARPF vs JNJ: Dividend Comparison 2026

PARPF yields 2000000.00% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PARPF wins by $4.879226400974806e+39M in total portfolio value
10 years
PARPF
PARPF
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full PARPF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — PARPF vs JNJ

📍 PARPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPARPFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PARPF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PARPF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PARPF
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, PARPF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PARPF + JNJ for your $10,000?

PARPF: 50%JNJ: 50%
100% JNJ50/50100% PARPF
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PARPF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PARPF buys
0
JNJ buys
0
No recent congressional trades found for PARPF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPARPFJNJ
Forward yield2000000.00% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$4.879226400974806e+39M$20.0K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$827.78
Total dividends collected$4.879195005460081e+39M$5.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PARPF vs JNJ ($10,000, DRIP)

YearPARPF PortfolioPARPF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$200,010,700$200,000,000.00$10,676$355.77+$200.00M → PARPF
2$3,738,731,768,458$3,738,517,757,009.35$11,407$389.39+$3738731.76M → PARPF
3$65,315,062,866,930,490$65,311,062,423,938,240.00$12,198$426.53+$65315062866.92M → PARPF
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$13,056$467.62+$1066400830062625.00M → PARPF
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$13,987$513.12+$16272182796453826560.00M → PARPF
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$14,998$563.56+$2.3205424011366188e+23M → PARPF
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$16,098$619.52+$3.0927990661046884e+27M → PARPF
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$17,295$681.69+$3.8524105697352695e+31M → PARPF
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$18,599$750.82+$4.484688260147987e+35M → PARPF
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$20,022$827.78+$4.879226400974806e+39M → PARPF

PARPF vs JNJ: Complete Analysis 2026

PARPF — Stock

Parx Materials N.V. engages in the manufacture and sale of antibacterial/antimicrobial plastics worldwide. The company offers its products for food contact applications and food packaging; medical devices and implants; textiles; pipes and drainages; and anti-fouling and hygiene applications, as well as to prevent mold and material deterioration; and biofilm formation. It holds a patented technology under the Saniconcentrate name. The company was formerly known as Parx Plastics N.V. and changed its name to Parx Materials N.V. in January 2020. Parx Materials N.V. was incorporated in 2012 and is headquartered in Rotterdam, the Netherlands.

Full PARPF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this PARPF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PARPF vs SCHDPARPF vs JEPIPARPF vs OPARPF vs KOPARPF vs MAINPARPF vs ABBVPARPF vs MRKPARPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.